Market PharmaPoint: Insomnia , Global Drug Forecast and Market Analysis to 2023
Insomnia is the most common sleep disorder and is believed to affect approximately 35% of the global population. The condition can be defined as patient-reported difficultly with sleep initiation or sleep maintenance which can include frequent awakenings, difficulty returning to sleep after awakenings, or awakening too early with inability to return to sleep. Cases of insomnia can be classified on the basis of etiology into primary and secondary (or comorbid) subtypes. The insomnia market is widely genericized creating a competitive environment for new products. As such, the treatment algorithm centers on the generically available nonbenzodiazepines and low-dose sedating antidepressants, despite the launch of numerous novel agents. The value of the insomnia market is set to further decline following the loss of exclusivity for Sunovion/Dainippon Sumitomo’s Lunesta, the top selling insomnia drug, in April 2014. However, GlobalData expects the launch of two pipeline products from a novel class of drugs to provide growth in the insomnia market as they may address some of the unmet need. Read Complete Report with TOC: http://www.marketresearchstore.com/report/pharmapoint-insomnia-global-drug-forecast-and-market-13806
Insomnia is the most common sleep disorder and is believed to affect approximately 35% of the global population. The condition can be defined as patient-reported difficultly with sleep initiation or sleep maintenance which can include frequent awakenings, difficulty returning to sleep after awakenings, or awakening too early with inability to return to sleep. Cases of insomnia can be classified on the basis of etiology into primary and secondary (or comorbid) subtypes. The insomnia market is widely genericized creating a competitive environment for new products. As such, the treatment algorithm centers on the generically available nonbenzodiazepines and low-dose sedating antidepressants, despite the launch of numerous novel agents. The value of the insomnia market is set to further decline following the loss of exclusivity for Sunovion/Dainippon Sumitomo’s Lunesta, the top selling insomnia drug, in April 2014. However, GlobalData expects the launch of two pipeline products from a novel class of drugs to provide growth in the insomnia market as they may address some of the unmet need.
Read Complete Report with TOC: http://www.marketresearchstore.com/report/pharmapoint-insomnia-global-drug-forecast-and-market-13806
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
4.3 <strong>Global</strong> Trends 39<br />
4.4 <strong>Forecast</strong> Methodology 41<br />
4.4.1 Sources Used 47<br />
4.4.2 Sources Not Used 48<br />
4.4.3 <strong>Forecast</strong> Assumptions <strong>and</strong> Methods 49<br />
4.5 Epidemiological <strong>Forecast</strong> for Acute <strong>Insomnia</strong> (2013-<strong>2023</strong>) 58<br />
4.5.1 Total Prevalent Cases of Acute <strong>Insomnia</strong> 58<br />
Read More: http://www.marketresearchs<strong>to</strong>re.com/report/pharmapointinsomnia-global-drug-forecast-<strong>and</strong>-market-13806
Change language